JP2022537339A - メラノーマバイオマーカー - Google Patents

メラノーマバイオマーカー Download PDF

Info

Publication number
JP2022537339A
JP2022537339A JP2021575276A JP2021575276A JP2022537339A JP 2022537339 A JP2022537339 A JP 2022537339A JP 2021575276 A JP2021575276 A JP 2021575276A JP 2021575276 A JP2021575276 A JP 2021575276A JP 2022537339 A JP2022537339 A JP 2022537339A
Authority
JP
Japan
Prior art keywords
autoantibodies
antigens
melanoma
patient
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537339A5 (enExample
Inventor
ガニング フィル
ブッデ ペトラ
ツフト ハンス‐ディエター
ブラウティガム マニュエル
Original Assignee
オンシミューン ジャーマニー ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンシミューン ジャーマニー ジーエムビーエイチ filed Critical オンシミューン ジャーマニー ジーエムビーエイチ
Publication of JP2022537339A publication Critical patent/JP2022537339A/ja
Publication of JP2022537339A5 publication Critical patent/JP2022537339A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
JP2021575276A 2019-06-19 2020-06-19 メラノーマバイオマーカー Pending JP2022537339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1908780.8 2019-06-19
GBGB1908780.8A GB201908780D0 (en) 2019-06-19 2019-06-19 Melanoma biomarkers
PCT/EP2020/067245 WO2020254658A1 (en) 2019-06-19 2020-06-19 Melanoma biomarkers

Publications (2)

Publication Number Publication Date
JP2022537339A true JP2022537339A (ja) 2022-08-25
JP2022537339A5 JP2022537339A5 (enExample) 2023-09-12

Family

ID=67432302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575276A Pending JP2022537339A (ja) 2019-06-19 2020-06-19 メラノーマバイオマーカー

Country Status (6)

Country Link
US (1) US20220317125A1 (enExample)
EP (1) EP3987289A1 (enExample)
JP (1) JP2022537339A (enExample)
CN (1) CN115176159A (enExample)
GB (1) GB201908780D0 (enExample)
WO (1) WO2020254658A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102534243B1 (ko) * 2022-12-05 2023-05-31 넥스탭 주식회사 Eomes 단백질을 표적으로 하는 인터페론-γ 조절 물질의 확인방법 및 이 물질을 포함하는 의약

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
CN116159127B (zh) * 2023-01-17 2024-04-02 西安交通大学医学院第一附属医院 酸性核糖体蛋白p2在治疗焦虑症中的应用
CN118311257B (zh) * 2024-03-22 2025-03-28 安徽师范大学 子宫颈神经内分泌癌标志物在制备子宫颈神经内分泌癌诊断试剂中的应用
CN118604339A (zh) * 2024-05-09 2024-09-06 深圳市第二人民医院(深圳市转化医学研究院) Snrpa蛋白检测试剂在制备肝癌诊断试剂盒中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
EP3724661A1 (en) * 2017-12-12 2020-10-21 Oncimmune Germany GmbH Melanoma checkpoint inhibitor detection and treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102534243B1 (ko) * 2022-12-05 2023-05-31 넥스탭 주식회사 Eomes 단백질을 표적으로 하는 인터페론-γ 조절 물질의 확인방법 및 이 물질을 포함하는 의약

Also Published As

Publication number Publication date
WO2020254658A1 (en) 2020-12-24
EP3987289A1 (en) 2022-04-27
GB201908780D0 (en) 2019-07-31
US20220317125A1 (en) 2022-10-06
CN115176159A (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
CN111337678B (zh) 与肿瘤免疫治疗效果相关的生物标志物及其应用
US20220317125A1 (en) Melanoma biomarkers
Savvateeva et al. Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis
US20210231663A1 (en) Melanoma checkpoint inhibitor detection and treatment
Amlani et al. Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis
CN102326080B (zh) A+生物标志物的试验
WO2016028699A2 (en) Biomarkers for diagnosis and management of neuro-immunological diseases
WO2013172926A1 (en) Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
US20150204866A1 (en) Auto-antigen biomarkers for lupus
KR20230074674A (ko) 면역 치료제에 대한 치료 반응성 예측용 바이오마커
JP2013539863A (ja) ループスのための自己抗原バイオマーカー
US20190128884A1 (en) Marker sequences for managing the therapy of rheumatoid arthritis patients
WO2014195730A2 (en) Auto-antigen biomarkers for lupus
Poulsen et al. Protein array-based companion diagnostics in precision medicine
JP2023123507A (ja) がんを治療するためのがん免疫
CN110687282A (zh) PD-1和/或p53自身抗体作为肿瘤疗效预测或预后评估的标志物
CN110687283B (zh) 自身抗体在诊断和/或治疗肿瘤中的应用
US20150293120A1 (en) Marker sequences for rheumatoid arthritis
EP3407067A1 (en) Method of detecting colitis ulcerosa by detection of autoantibodies
US20190120834A1 (en) Marker sequences for rheumatoid arthritis
EP2551673B1 (en) Methods for the detection of cancer infiltration of the central nervous system
US20110177966A1 (en) method for predicting the response to a treatment with anakinra
WO2013039166A1 (ja) 抗ｗｔ１抗体の測定方法
US20190353657A1 (en) Method of improving efficacy of melanoma treatment
CN114736967B (zh) 预测免疫检查点抑制剂疗法原发耐药的标志物及方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806